Sanofi's Xenpozyme Is First Drug Approved For Rare Genetic Disease ASMD
The US FDA approved the enzyme replacement therapy for the condition also known as Niemann-Pick disease; it will be priced at a median annual cost of $780,000 per year.
The US FDA approved the enzyme replacement therapy for the condition also known as Niemann-Pick disease; it will be priced at a median annual cost of $780,000 per year.